Tumor-resident Tregs co-express high levels of CTLA-4, OX-40, and GITR compared to effector T-cells, and in murine models of mesothelioma, the combination of anti-OX-40 and anti-CTLA-4 has a synergistic effect and results into a 20% to 80% increase in tumor regression as compared to single-antibody treatment [89]. Here, TNFRSF18 is linked to neoplasm.